A case of rhino-orbital-cerebral mucormycosis

Aishwarya Venkataraman, Bridget Callaghan

ABSTRACT

Abstract is not required for Clinical Images
A case of rhino-orbital-cerebral mucormycosis

Aishwarya Venkataraman, Bridget Callaghan

CASE REPORT

A 16-year-old, neutropenic boy on treatment for acute lymphoblastic leukemia developed acute onset fever and swelling of the left eye. The initial differential diagnoses were periorbital cellulitis and orbital cellulitis. Ophthalmological examination showed no eye movements, no pupillary reaction, no perception of light and a swollen retina. An urgent computed tomography (CT) scan of head with orbits was suggestive of orbital cellulitis and broad spectrum antibiotics (piperacillin/tazobactam and amikacin) were commenced. A detailed ENT examination on the same day revealed possible spores or hyphae along the nasal septum on the left side 2 cm from the nostril. Mucormycosis was suspected and he was started on antifungals (amphotericin B and posaconazole) in addition to the antibiotics. Magnetic resonance imaging (MRI) scan of the brain and orbits performed the next day, showed extensive infiltration consistent with infection of the left orbit, left maxillary antrum and ethmoidal sinus, extending to the right medial nasal region (Figure 1A, arrow and Figure 1B, arrow). Subsequently, he underwent debridement and enucleation of the left eye with radical bilateral frontoethmoidectomy to salvage the right eye. Histology
confirmed widespread necrotizing, angioinvasive and perineural fungal infection with involvement of sclera, choroid and dura. Culture grew Rhizopus microsporus, Staphylococcus aureus and Acinetobacter species. Despite optimum treatment, he succumbed to extensive central nervous system disease 40 days after initial presentation.

**DISCUSSION**

Mucormycosis is a rare, rapidly destructive fungal infection most commonly affecting immunocompromised and diabetic patients [1–4]. Depending on the anatomical site involved, it can be broadly classified as rhino-orbital-cerebral, pulmonary, gastrointestinal, cutaneous or disseminated disease [1, 2]. The fungus is angioinvasive, causing severe thrombosis and tissue necrosis [1]. Underlying predisposing conditions are major risk factors for the disease [1–4]. In our case, chemotherapy-induced neutropenia (ANC of the patient remained <1.0x10^9/l throughout) was one of the risk factors. Steroids, used in treatment of ALL, may also increase the risk of fungal infection [2, 3]. The initial symptoms of rhino-orbital-cerebral mucormycosis is similar to either sinusitis or periorbital cellulitis. If untreated, infection can spread to the orbit from the ethmoid sinuses, resulting in loss of extraocular muscle function and proptosis. Progressive vision loss and ultimately blindness may result either from involvement of the optic nerve or from cavernous sinus thrombosis. Extensive central nervous system involvement can present with signs and symptoms of cerebral infarctions secondary to internal carotid artery and cavernous sinuses thrombosis [1].

Diagnosis of rhino-orbital-cerebral mucormycosis is challenging. Initial CT scan findings can be negative or have findings suggestive of sinusitis. MRI scans are more sensitive than CT scans for detecting disease beyond the sinuses [5]. Confirmatory diagnosis is made by histopathological examination and positive microbiology culture. Unfortunately, this is time consuming and Mucorales species often fail to grow in fungal culture [1].

Antifungal therapy alone is usually insufficient to control the rapidly spreading disease. It is important to treat or reverse the underlying cause and immunosuppressive medications should be dose reduced or stopped if possible [1–3]. Angioinvasion, thrombosis, and tissue necrosis result in poor penetration of anti-fungal agents to the site of infection. Surgical excision of the infected sinuses and appropriate debridement of the retro-orbital space is often required and can prevent the spread of infection into the eye, resulting in improved cure rates [1]. Unfortunately, mortality and morbidity remains high despite appropriate medical and surgical treatment [1, 6]. The patient described in the case report developed extensive cerebral and brain stem infarction due to the rapidly spreading disease despite prompt diagnosis and treatment.

**CONCLUSION**

Rhino-orbital-cerebral mucormycosis is rare but potentially fatal in immunocompromised patients. Diagnosis is often difficult and surgical debridement, prompt use of antifungal agents and reversal of predisposing factors, if possible remains the mainstay of treatment. Despite optimum treatment, the mortality remains high; more than 50%. Newer tools are urgently needed to diagnose and treat mucormycosis.

**Keywords:** Angio-invasive, Anti-fungal, Fungal infection, Mucormycosis, Posaconazole

---

**How to cite this article**

Venkataraman A, Callaghan B. A case of rhino-orbital-cerebral mucormycosis. Int J Case Rep Images 2015;6(11):724–726.

doi:10.5348/ijcri-201534-CL-10089

**********

**Author Contributions**

Aishwarya Venkataraman – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Bridget Callaghan – Substantial contributions to conception and design, Revising the article critically for important intellectual content, Final approval of the version to be published

**Guarantor**

The corresponding author is the guarantor of submission.

**Conflict of Interest**

Authors declare no conflict of interest.

**Copyright**

© 2015 Aishwarya Venkataraman et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

**REFERENCES**

1. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005 Jul;18(3):556–69.
2. Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J Pediatr Hematol Oncol 2009 Dec;31(12):911–9.

3. Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with hematologic malignancies. Int J Clin Pract 2009 Jan;63(1):134–9.

4. Thomas S, Singh VD, Vaithilingam Y, Thayil SC, Kothari R. Rhinocerebral mucormycosis—a case report. Oral Maxillofac Surg 2012 Jun;16(2):233–6.

5. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008 Aug 1;47(3):364–71.

6. Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010 Nov;12(6):423–9.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Weed Journals: On Web  Browse Journals